DECEMBER 5-9, 2023

HENRY B. GONZALEZ CONVENTION CENTER

SAN ANTONIO, TEXAS

SABCS-2023-cluster-logo-reverse
Preliminary Program

PRELIMINARY PROGRAM 

Working titles/topics shown. Final titles and speakers will follow.
In person and virtual attendance is available.


Tuesday, December 5, 2023 All times are CENTRAL Time


12:00 pm - 1:55 pm

CONCURRENT SPECIAL SESSIONS


Special Session 1: New Drug Approvals for Metastatic Breast Cancer, Hemisfair Ballroom 1-2

Session Co-Moderator: Laleh Amiri-Kordestani, U.S. Food and Drug Administration, Silver Spring, Maryland

Session Co-Moderator: Martine J. Piccart, Institut Jules Bordet, Brussels, Belgium

 

Elacestrant
Mirat Shah, US Food and Drug Administration, Silver Spring, Maryland

Trastuzumab deruxtecan
Preeti Narayan, US Food and Drug Administration, Silver Spring, Maryland

Late breaking (new drugs currently under review)
Christy Osgood, US Food and Drug Administration, Silver Spring, Maryland


Panel Discussion

Janice Cowden, Metastatic Breast Cancer Alliance, Bradenton, Florida

Virginia Kaklamani, UT Health San Antonio, San Antonio Texas

Vassiliki Karantza, Merk Research Laboratories, Rahway, New Jersey

Flora Mulkey, US Food and Drug Administration, Silver Spring, Maryland

Additional panelist to be announced


Special Session 2: Prevention, Early Detection, and Interception, Stars at Night Ballroom 3-4
Moderator: Carol J. Fabian, University of Kansas Medical Center, Kansas City, Kansas

What is polygenic risk score and how is it used?
Suzette Delaloge, Gustave Roussy, Villejuif, France

Questions and Discussion


Hormone replacement and alternatives for women at population and moderately increased risk

Carol J. Fabian, University of Kansas Medical Center, Kansas City, Kansas

Cancer risk associated with exogenous hormone use in BRCA mutation
Joanne Kotsopoulos, Women's College Research Institute, Toronto, Ontario, Canada

 

Panel Discussion

 

Special Session 3: Social Determinants of Health— Impact on Cancer Care, Stars at Night Ballroom 1-2
Moderator: Amelie G. Ramirez, UT Health Science Center at San Antonio, San Antonio, Texas

What are social determinants of health and why are they important to cancer care?
Amelie G. Ramirez, UT Health Science Center San Antonio, San Antonio, Texas

Multilevel barriers to addressing social risks: Data from select NCI cancer settings

Brenda Adjei, National Cancer Institute, Bethesda, Maryland


How do hospitals/clinics utilize SDoH data?

Brian M. Rivers, Morehouse School of Medicine Cancer Health Equity Institute, Atlanta, Georgia


Once social determinants of health are determined, what processes need to be in place to reduce the burden on patients?
Sandi L. Pruitt, UT Southwestern Medical Center, Dallas, Texas

How is the impact of SDoH being evaluated at clinical/hospital and community levels?
Susan T. Vadaparampil, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Advocate response
Barbara Segarra, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

Panel Discussion



1:55 pm - 2:05 pm BREAK
2:05 pm - 3:05 pm

CONCURRENT WORKSHOPS


Clinical Workshop: Tumor Agnostic Approaches to Care, Stars at Night Ballroom 1-2

Moderator: Sangeetha M. Reddy, UT Southwestern Medical Center, Dallas, Texas

Agnostic trials in the field of targeted therapies
Vivek Subbiah, UT MD Anderson Cancer Center, Houston, Texas

ADC development across tumor types
Joshua Z. Drago, Memorial Sloan Kettering Cancer Center, New York, New York

Real-world data
Mia A. Levy, Foundation Medicine, Inc., Cambridge, Massachusetts

Defining a biologic entity that is sensitive to immunotherapeutic
Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands



Materials and Methods: Basic Science to Breast Oncology Workshop, Stars at Night Ballroom 3-4
Moderator: Neil Vasan, Columbia University Irving Medical Center, New York, New York

Organoids
Calvin J. Kuo, Stanford University, Stanford, California

Single-cell sequencing
Speaker to be announced

Real-world genomics
Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

Drug engineering and discovery
John Irwin, University of California San Francisco, San Francisco, California

3:05 pm - 3:25 pm BREAK
3:25 pm - 5:15 pm CONCURRENT EDUCATIONAL SESSION BLOCK #1

ED01: Latest Trends in Adjuvant Endocrine Therapy, Stars at Night Ballroom 3-4
Moderator: Fabrice André, Gustave Roussy, Villejuif, France

Optimizing endocrine therapy in premenopausal women
Vered Stearns, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

How to treat postmenopausal patients
Rachel Freedman, Dana-Farber Cancer Institute, Boston, Massachusetts

Who benefits from CDK 4/6 inhibitors and chemotherapy in the adjuvant setting?
Otto Metzger, Dana-Farber Cancer Institute, Boston, Massachusetts

ED02: Lobular Breast Cancer, Stars at Night Ballroom 1-2
Moderator: Steffi Oesterreich, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Biological peculiarities of ILC
Christine Desmedt, KU Leuven, Leuven, Belgium

Diagnosis, prognosis, and surveillance: What is different?
Tari A. King, Dana-Farber Cancer Institute, Boston, Massachusetts

Innovative approaches for lobular breast cancer
Jason Aboudi Mouabbi, UT MD Anderson Cancer Center, Houston, Texas

Panelist: Siobhán Freeney, European Lobular Breast Cancer Foundation, Dublin, Ireland

ED03: Overcoming Obesity-Associated Breast Cancer Risk, Hemisfair Ballroom 1-2
Moderator: Abenaa M. Brewster, UT MD Anderson Cancer Center, Houston, Texas

How much weight loss is needed to break the obesity-cancer link?
Stephen D. Hursting, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Interventions: Medical and lifestyle
Randy Seeley, University of Michigan, Ann Arbor, Michigan

Impact of exercise on breast cancer outcomes
Kerry S. Courneya, University of Alberta, Edmonton, Alberta, Canada

 

Panelist: Joanne Taylor, Abcdiagnosis, London, England


ED04: Treatment Post-CDK 4/6 Inhibitors, Hemisfair Ballroom 3
Moderator: Stephanie Graff, Lifespan Cancer Institute, Providence, Rhode Island

Single agent endocrine therapy
Carlos H. Barrios, Latin American Cooperative Oncology Group, Porto Alegre, Brazil

Combination endocrine therapy
Ruth O’Regan, University of Rochester, Rochester, New York

When to transition to cytotoxics
Erica Stringer-Reasor, University of Alabama at Birmingham, Birmingham, Alabama

Panelist: Abigail Johnston, Surviving Breast Cancer, Orlando, Florida
5:15 pm - 5:30 pm BREAK
5:30 pm - 6:30 pm

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #1

PS1 Less is More: Minimizing Surgical Treatment in Patients with Early Stage Breast Cancer, Stars at Night Ballroom 3-4

PS2 Improving QOL and Care delivery for the Breast Cancer Patient, Hemisfair Ballroom 1-2

PS3 Insights from Single Cell, Spatial, and Artificial Intelligence Approaches, Stars at Night Ballroom 1-2


Wednesday, December 6

7:00 am - 8:00 am

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #2 

PS4 Gaps in the Timing, Treatment Selection, and Supportive Services for Cancer Care, Stars at Night Ballroom 3-4, 

PS5 Shining a New Light on Breast Cancer: Novel Molecular and Functional Imaging Approaches to Detect and Characterize Breast Cancer, Hemisfair Ballroom 1-2

PS6 Prognostic and Predictive uses of cell free DNA, Stars at Night Ballroom 1-2

8:00 am - 8:15 am  BREAK
8:15 am - 8:30 am

Welcome and Opening Remarks, Hall 1

8:30 am - 9:00 am 

William L. McGuire Memorial Lecture, Hall 1

Jack Cuzick, Queen Mary University of London, London, England

9:00 am - 12:00 pm  GENERAL SESSION 1, Hall 1
12:00 pm  EXHIBITS OPEN, Halls 2-3
12:00 pm - 2:00 pm 

POSTER SESSION 1, Halls 2-3

12:00 pm - 1:00 pm Rapid Fire: Mini-Oral Presentations, Hemisfair Ballroom 1-2
1:00 pm - 2:00 pm    CONCURRENT SESSIONS

Debate: Anthracyclines…To give or not to give? Stars at Night Ballroom 1-2
Moderator: Harold J. Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts

“For”
Martine J. Piccart, Institut Jules Bordet, Brussels, Belgium


“Against”
Virginia F. Borges, University of Colorado Anshutz Medical Campus, Aurora, Colorado


State-of-the-Art Session 1: Immunotherapy— Purpose, Resistance, and Toxicity, Stars at Night Ballroom 3-4
Moderator: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Biomarkers predicting immune related adverse events
Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, Massachusetts

Cellular therapies: What is the outlook for breast and other solid cancers?
Valentina Hoyos Velez, Baylor College of Medicine, Houston, Texas

Tumor mechanisms of resistance to immunotherapy
Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Chromosomal instability and resistance to immunotherapy
Kevin Litchfield, University College London, London, England

2:00 pm - 3:00 pm 

Molecular Tumor Board,  Hemisfair Ballroom 1-2

Moderator: Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

Panelists:

Giuseppe Curigliano, European Institute of Oncology, Milan, Italy

Gaorav Gupta, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Maryam Shirazi, Tempus Labs, Inc., Chicago, Illinois

Nancy U. Lin, Dana-Farber Cancer Institute, Boston, Massachusetts

Elizabeth A. Morris UC Davis School of Medicine, Sacramento, California

Joyce A. O'Shaughnessy, Baylor University Medical Center, Dallas, Texas


3:00 pm - 3:10 pm BREAK
3:10 pm - 5:00 pm

CONCURRENT EDUCATIONAL SESSION BLOCK #2


ED05: Controversies in Local Regional Management, Hemisfair Ballroom 1-2
Moderator: Debra Patt, Texas Oncology, Austin, Texas

Demystifying the axilla: Challenging scenarios in the upfront surgery setting and after neoadjuvant chemotherapy
Andrea V. Barrio, Memorial Sloan Kettering Cancer Center, New York, New York

When less is more: Patient-friendly radiation courses with WBI and PBI
Icro Meattini, Università degli Studi di Firenze, Florence, Italy

Surgical management of clinical stage I HER 2+ and triple negative breast cancer
Anita Mamtani, Memorial Sloan Kettering Cancer Center, New York, New York

Optimizing outcomes: Breast reconstruction technique and timing after mastectomy
Marco Maricevich, Baylor College of Medicine, Houston, Texas

 

Panelist: Jamie LaScala, Translational Center of Excellence in Breast Cancer, Penn Medicine, Philadelphia, Pennsylvania


ED06: Coordinated Care of Brain Metastasis, Hemisfair Ballroom 3
Moderator: Carey K. Anders, Duke University Comprehensive Cancer Center, Durham, North Carolina
Speakers:
Rebecca Dent, National Cancer Centre Singapore, Singapore
Christopher D. Lascola, Duke University Medical Center, Durham, North Carolina
Nelson Moss, Memorial Sloan Kettering Cancer Center, New York, New York
Helen A. Shih, Massachusetts General Hospital, Boston, Massachusetts
Jeffrey Wefel, UT MD Anderson Cancer Center, Houston, Texas

ED07: HER2+ Breast Cancer— Updates from the Clinic and the Lab, Stars at Night Ballroom 1-2
Moderator: Mothaffar F. Rimawi, Baylor College of Medicine, Houston, Texas

Molecular determinates of response and resistance in HER2+ breast cancer
Ron Bose, Washington University School of Medicine in St. Louis, St. Louis, Missouri

Recent advances in systemic disease
Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Management of brain metastases
Sarah L. Sammons, Dana-Farber Cancer Institute, Boston, Massachusetts
Panelist: Terlisa Sheppard, Terlisa Fights Breast Cancer, Inc., Florida

ED08: Toxicity Management— Next-Gen Therapies Means Next-Gen Toxicities, Stars at Night Ballroom 3-4
Moderator: Antonio C. Wolff, Johns Hopkins University, Baltimore, Maryland

Antibody drug conjugates
Heather L. McArthur, UT Southwestern Medical Center, Dallas, Texas

Targeted therapeutics in hormone positive breast cancers
Erica L. Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts

Immunotherapies: short and long term
Douglas B. Johnson, Vanderbilt University Medical Center, Nashville, Tennessee

Panelist: Sheila Johnson, Komen Advocates in Science, Swansea, Illinois
5:00 pm - 7:00 pm    

POSTER SESSION 2, Halls 2-3

5:30 pm - 6:30 pm 

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #3

PS7 Prevention, Stars at Night Ballroom 3-4

PS8 Antibody Drug Conjugates: Where are we headed? Hemisfair Ballroom 1-2

 PS9 Exploiting Tumor Biology in HER2-positive Breast Cancer to Escalate or De-escalate Neoadjuvant Therapy, Stars at Night Ballroom 1-2

7:00 pm 

EXHIBITS CLOSE, Halls 2-3


Thursday, December 7

7:00 am - 8:00 am

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #4 

PS10 Refining Prediction of Cancer Risk and Outcomes, Stars at Night Ballroom 3-4

PS11 CNS Disease in Breast Cancer: Where are We Now and Can We do Better? Hemisfair Ballroom 1-2

PS12 Putting Brakes on the Cell Cycle: Understanding Mechanisms Governing CDK 4/6 inhibitor Resistance and Role for Novel Therapeutic Strategies, Stars at Night Ballroom 1-2

8:00 am - 8:15 am  BREAK
8:15 am - 11:15 am

General Session 2, Hall 1

11:20 am - 11:50 am 

Plenary Lecture 1, Hall 1

Breast cancer evolution, immune evasion and metastasis driven by chromosomal instability
Charles Swanton, The Francis Crick Institute, London, England

11:50 am - 12:00 pm  BREAK
12:00 pm  EXHIBITS OPEN, Halls 2-3
12:00 pm - 2:00 pm 

POSTER SESSION 3, Halls 2-3

1:00 pm - 1:30 pm AACR Distinguished Lectureship in Breast Cancer Research, supported by Aflac Inc., Stars at Night Ballroom 1-2
1:00 pm - 2:00 pm    CONCURRENT SESSIONS

Clinical Case Discussions, Stars at Night Ballroom 3-4
Moderator: Matthew P. Goetz, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Panelists:
Fabrice André, Gustave Roussy, Villejuif, France
Nadia Harbeck, LMU University Hospital, Munich, Germany
Erica L. Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts
Aleix Prat, Hospital Clínic Barcelona, Barcelona, Spain
Hope S. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California


State-of-the-Art Session 2: Implications of Senescence for Breast Cancer Biology and Treatment, Hemisfair Ballroom 1-2
Moderator: Justin M. Balko, Vanderbilt University, Nashville, Tennessee

Cellular senescence: The Senescence-Associated Secretory Phenotype (SASP) and immunity
Marcus Ruscetti, UMass Chan Medical School, Worcester, Massachusetts

Implications of therapy induced senescence in breast cancer
James G. Jackson, Tulane University School of Medicine, New Orleans, Louisiana

Clinical trials and new therapeutics
Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Australia

2:00 pm - 3:00 pm 

Clinical Controversies, Stars at Night Ballroom 3-4

Moderator: Lisa A. Carey, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Are we ready to stop staging the axilla?  
Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York
Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, California

How to treat small triple negative breast cancer  
Priyanka Sharma, University of Kansas Medical Center, Kansas City, Kansas
Alexandra Thomas, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

Biology or stage? Tailoring treatment for premenopausal women with nodal involvement, but low oncotype  
Eric P. Winer, Yale Cancer Center, New Haven, Connecticut
Kevin M. Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia

3:00 pm - 3:10 pm  BREAK
3:10 pm - 5:00 pm

CONCURRENT EDUCATIONAL SESSION BLOCK #3


ED09: Genomics for Clinical Research and Cancer Care, Stars at Night Ballroom 1-2  
Moderator: Norah Lynn Henry, Rogel Cancer Center University of Michigan, Ann Arbor, Michigan

Actionable mutations in breast cancer: Targeting the pathway
Milan Radovich, Caris Life Sciences, Irving, Texas

Tumor tissue vs. ctDNA
Ben O'Leary, Royal Marsden Hospital, London, England

When do you order and how to interpret genomic testing
Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York

ED10: PI(3)king the Right Target, Stars at Night Ballroom 3-4  
Moderator: Cynthia X. Ma, Washington University Siteman Cancer Center, Saint Louis, Missouri

PI3 Kinase
Neil Vasan, Columbia University Irving Medical Center, New York, New York

AKT pathway
Alex Toker, Beth Israel Deaconess Medical Center, Boston, Massachusetts

mTOR pathway
Robert J. Schneider, NYU Grossman School of Medicine, New York, New York

ED11: Inflammatory Breast Cancer: Clinical Challenges, Evolving Concepts and Novel treatments (People’s Choice), Hemisfair Ballroom 1-2  
Moderator: Filipa Lynce, Dana-Farber Cancer Institute, Boston, Massachusetts

Is IBC a genomically different type of BC?
Frederick Howard, University of Chicago, Chicago, Illinois

Surgical controversies in IBC
Antony Lucci, UT MD Anderson Cancer Center, Houston, Texas

Approaches to radiation therapy in IBC
Jennifer Bellon, Dana-Farber Cancer Institute, Boston, Massachusetts

Panelists:
Terry Arnold, The IBC Network Foundation, Sealy, Texas
Ginny Mason, Inflammatory Breast Cancer Research Foundation, Broadway, Virginia
5:00 pm - 7:00 pm    

POSTER SESSION 4, Halls 2-3

5:30 pm - 6:30 pm 

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #5

PS13 Special Populations: Pregnancy, Male and Geriatric Patients, Stars at Night Ballroom 3-4

PS14 Setting Expectations for Toxicities Related to I/O Therapy, Hemisfair Ballroom 1-2

PS15 Novel Nuclear Receptor Targeting Therapies, Stars at Night Ballroom 1-2

7:00 pm 

EXHIBITS CLOSE, Halls 2-3


Friday, December 8

7:00 am - 8:00 am

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #6

PS16 Enhancing Immunotherapy for Triple Negative Breast Cancer: Novel Therapies and Biomarkers, Stars at Night Ballroom 3-4

PS17: Biomarkers of Response and/or Resistance to Endocrine Based Therapies: Implications for Treatment Approaches, Hemisfair Ballroom 1-2

PS18 Disparate Care calls for Desperate Measures:  Understanding Gaps in Quality of Care and Opportunities to Improve it, Stars at Night Ballroom 1-2

8:00 am - 8:15 am  BREAK
8:15 am - 11:15 am

General Session 3, Hall 1  

11:15 am - 11:45 am 

Plenary Lecture 2, Hall 1  

Recent advances in triple negative breast cancer
Melinda L. Telli, Stanford University School of Medicine, Stanford, California
11:45 am - 12:00 pm  BREAK
12:00 pm  EXHIBITS OPEN, Halls 2-3
12:00 pm - 2:00 pm 

POSTER SESSION 5, Halls 2-3  

1:00 pm - 1:30 pm

AACR Outstanding Investigator Award for Breast Cancer Research, supported by the Breast Cancer Research Foundation, Stars at Night Ballroom 1-2

1:30 pm - 2:30 pm    CONCURRENT SESSIONS

Translational Research Controversies, Stars at Night Ballroom 3-4
Moderator: Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

Baby-TAM  
Per Hall, Karolinska Institutet, Stockholm, Sweden
Jack Cuzick, Queen Mary University of London, London, England
  
When to do a window trial
Mitchell Dowsett, Royal Marsden Hospital, London, England
Sara A. Hurvitz, UCLA – University of California Los Angeles, Los Angeles, California
  
Are we sequencing too late?
Charles M. Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Fabrice André, Gustave Roussy, Villejuif, France

  
State-of-the-Art Session 3: Targeting Mutant ER, Hemisfair Ballroom 1-2  
Moderator: Aditya Bardia, Massachusetts General Hospital, Boston, Massachusetts

Biological consequences of ESR1 mutation
Geoffrey L. Greene, University of Chicago, Chicago, Illinois

Tracking mutant ER using ctDNA
François-Clément Bidard, Institut Curie, Paris, France

The future of oral SERDs
Erika P. Hamilton, Sarah Cannon Research Institute, Nashville, Tennessee


2:30 pm - 2:45 pm 

BREAK  

2:45 pm - 3:45 pm
Year in Review, Hall 1
Moderator: Carlos L. Arteaga, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas

Advanced Breast Cancer
Mariana Chavez-Mac Gregor, UT MD Anderson, Houston, Texas

Early Breast Cancer
Ann H. Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts

Basic Science

Heide L. Ford, University of Colorado Denver School of Medicine, Denver, Colorado


Translational
Jennifer K. Richer, University of Colorado Anshutz Medical Campus, Aurora, Colorado

3:45 pm - 4:00 pm    

BREAK

4:00 pm

Exhibits Close, Hall 2-3

4:00 pm - 6:00 pm 
View from the Trenches: What will You do on Monday Morning? Hall 1
Moderator: Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, Massachusetts

Panelists:
Javier Cortes Castan, Ramón y Cajal University Hospital, Madrid, Spain
Lesley Glenn, Project Life, Central Point, Oregon
Sara A. Hurvitz, University of California Los Angeles, Los Angeles, California
Joyce A. O'Shaughnessy, Baylor University Medical Center, Dallas, Texas
Richard C. Zellars, Indiana University School of Medicine, Indianapolis, Indiana

Saturday, December 9

8:00 am - 12:00 pm

Career Development Forum

8:00 am - 8:45 am Achieving Your Career Goals: Lessons from a Successful Scientist, Stars at Night Ballroom 1-2
Moderator: Kate Lathrop, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX

Speaker to be announced
8:45 am - 9:00 am  BREAK
9:00 am - 11:00 am Concurrent Workshops for Early Career Scientists (pre-registration required)

Planning Your First Clinical Trial, Room 302
This workshop for residents, fellows, and early-stage clinical faculty will consist of a 60-minute panel discussion with expert clinical trialists followed by breakout into small groups for peer-to-peer evaluation of a clinical trial concept. 

Panelists:

Carole Baas, Alamo Breast Cancer Foundation, Southlake, Texas
Thomas Braun, University of Michigan, Ann Arbor, Michigan
Dawn L. Hershman, Columbia University Medical Center, New York, New York
Ruth O’Regan, University of Rochester, Rochester, New York
Additional panelists to be announced


Grant Writing Tips and Tricks, Room 303
This workshop for graduate students, fellows, and early-stage faculty will consist of a 60-minute panel discussion with expert grant writers and reviewers followed by breakout into small groups for peer-to-peer evaluation of a specific aims page. 


Panelists:
David Gius, Mays Cancer Center at UT Health San Antonio, San Antonio, Texas
Reuben S. Harris, UT Health San Antonio, San Antonio, Texas
Additional panelists to be announced
 9:00 am - 12:00 pm Navigating Success: Women’s Career Development (pre-registration required), Room 304

Designed for women who have completed their traineeships, this workshop is a dynamic and inclusive event aimed to inspire and support women pursuing careers in scientific research. The workshop provides a platform for accomplished female scientists to share their experiences, offer mentorship, and discuss strategies to overcome gender-related challenges in the field. Through engaging talks, interactive sessions, and networking opportunities, participants gain valuable insights, build a strong support network, and acquire tools to thrive and excel in their scientific research careers.

Setting the stage for success
Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts 

Evidence-based strategies to address systemic barriers facing women researchers
Reshma Jagsi, Emory University, Atlanta Georgia

Title to be announced
Amelie Ramirez, UT Health Sciences Center at San Antonio, San Antonio, Texas

Additional Speakers to be announced

Interactive Portion of Workshop
Anne Welsh,Psychologist and Executive Coach, Cambridge, Massachusetts


 11:00 am -12:00 pm Networking and Career Roundtable Discussions (pre-registration required), Stars at Night Ballroom 1-2

The Networking and Career Roundtables provide interactive informational interviews with experts on a variety of topics that are important for career development. These discussions provide attendees with an opportunity to speak face-to-face with colleagues and potential collaborators. Early career investigators are encouraged to participate for the opportunity to meet respected senior investigators and connect with researchers of similar interests. Light refreshments will be provided. Topics and mentors to be announced.